Transgenic knockout studies (23) and shRNA experiments on pancreatic cancer cells show that suppression of the RAS/RALGEF/RAL pathway inhibits the tumorigenic phenotype and the metastatic process, but does not have a severe impediment on normal cellular growth (20, 21, 34). The gene discussed is RALGDS; the disease is pancreatic neoplasm.